A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial

Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial

(2016) L. A. Morrow et al.   DIABETES OBESITY & METABOLISM

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

(2016) K. Cusi et al.   DIABETES OBESITY & METABOLISM

Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

(2016) T. Blevins et al.   DIABETES OBESITY & METABOLISM

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial

(2016) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5

(2015) John B. Buse et al.   DIABETES CARE

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

(2014) Robert R. Henry et al.   DIABETES CARE

Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice

(2014) P. Rossetti et al.   DIABETES OBESITY & METABOLISM

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease

(2014) Maryann Maximos et al.   HEPATOLOGY

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects

(2014) Vikram P. Sinha et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

(2013) M. C. Moore et al.   DIABETES

The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010

(2013) S. Stark Casagrande et al.   DIABETES CARE

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus

(2013) V. P. Sinha et al.   DIABETES OBESITY & METABOLISM

Treat-to-target trials: uses, interpretation and review of concepts

(2013) A. J. Garber   DIABETES OBESITY & METABOLISM

Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus

(2013) D. M. Karl et al.   DIABETES OBESITY & METABOLISM

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

(2011) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

General Multistage Gatekeeping Procedures

(2008) Alex Dmitrienko et al.   BIOMETRICAL JOURNAL